Dr. Benjamin Levinson is DP Clinical’s Chief Medical Officer and brings nearly 40 years of experience in the supervision, oversight, reporting and direct participation in the clinical safety, efficacy, and tolerability of therapeutics under development for Phase I-IV clinical trials. At DP Clinical, Dr. Levinson is responsible for the evaluation, management, and reporting of study safety events. He also handles medical writing requirements for the company, including input on study design, protocol development, and clinical study reports. His experience spans many therapeutic areas including neuroscience (particularly spinal cord injury), cardiovascular, haemotology, infectious disease, lipidology, oncology, osteoporosis, pain management, psychiatry, respiratory, and schizophrenia.
Dr. Levinson received his Doctor of Medicine at Rutgers Medical School and completed his residency in Internal Medicine at Robert Wood Johnson Hospital after which he joined the Department of Clinical Pharmacology at E.R. Squibb (currently Bristol Myers Squibb) where he progressed to Associate Director of Clinical Research in Hypertension and was instrumental in the approval of Monopril (fosinopril). He then moved to Anaquest, a Division of BOC Gases, as Senior Associate Director and contributed to the approval of Revex (nalmefene). His next assignment was as Director and then Vice-President of Drug Development at Well Spring/InfaCare having responsibility for all pre-clinical and clinical development of stannsoporphin. He then joined Reliant where he worked on Omega-3 fatty acids research. P, Dr. Levinson was the Senior Director of Clinical Research at Daichi Sankyo in the field of Spinal Cord Injury as well as studies of other medications targeted for neurological disorders and medications for Chronic Obstructive Lung Disease.
